CYTOSORBENTS CRP
NASDAQ: CTSO (Cytosorbents Corporation)
Kemas kini terakhir: 3 jam lalu7.00
6.65 (1,900.57%)
| Penutupan Terdahulu | 0.350 |
| Jumlah Dagangan | 462,305 |
| Harga / Jualan (P/S) | 0.590 |
| Harga / Buku (P/B) | 11.43 |
| Julat 52 Minggu |
| Margin Keuntungan | -45.59% |
| Margin Operasi (TTM) | -44.54% |
| EPS Cair (TTM) | -0.290 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -2.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 185.50% |
| Nisbah Semasa (MRQ) | 2.61 |
| Aliran Tunai Operasi (OCF TTM) | -13.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -9.67 M |
| Pulangan Atas Aset (ROA TTM) | -20.46% |
| Pulangan Atas Ekuiti (ROE TTM) | -96.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Cytosorbents Corporation | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.50 |
|
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 15.29% |
| % Dimiliki oleh Institusi | 27.77% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Avenir Corp | 30 Jun 2026 | 5,189,218 |
| Skylands Capital, Llc | 30 Jun 2026 | 1,211,400 |
| Sargent Investment Group, Llc | 30 Jun 2026 | 555,757 |
| Cibc Bancorp Usa Inc. | 30 Jun 2026 | 172,649 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |